APPLICATION
ANDA207835
TYPE
ANDA
ORIGINAL APPROVAL
2017-03-07
LATEST ACTION
2020-02-09
ROUTE
ORAL
DOSAGE FORM
TABLET, ORALLY DISINTEGRATING
MARKETING STATUS
Discontinued
Products
RIZATRIPTAN BENZOATEDiscontinued
RIZATRIPTAN BENZOATE EQ 10MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
RIZATRIPTAN BENZOATEDiscontinued
RIZATRIPTAN BENZOATE EQ 5MG BASE · TABLET, ORALLY DISINTEGRATING · ORAL
Approval history
2020-02-09Labeling · Supplement 3 · standardAP
2017-03-07UNKNOWN · Original · standardAP
Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.
Weekly Briefing
Read a past issue →Get the Weekly GxP Briefing
Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.